What's the Future for the Allergan, Pfizer Deal?

The transcript discusses Allergan's strong performance and its strategic moves, including the sale of its generics business to Teva and its deal with Pfizer. It also covers the potential impact of US Treasury regulations on these deals. Valeant's financial challenges, including its debt and cash flow issues, are examined, along with its distribution model changes. The transcript concludes with an overview of M&A trends in the pharmaceutical industry, highlighting a shift towards smaller deals and new science.

What were the strong results mentioned in the conference call?

How might the delay in selling the generics business to Teva impact the deal with Pfizer?

What is the significance of the US Treasury Department's involvement mentioned in the text?

What guidance did the company provide regarding their base branded growth?

What concerns were raised regarding Valeant's cash flow and debt management?

What challenges does Valeant face in terms of their distribution model?

What are the expectations for M&A activity in the pharmaceutical industry this year?